Ultragenyx agrees to sell a rare‑pediatric disease priority‑review voucher for $203 million
Ultragenyx Pharmaceutical announced that it will transfer a Rare Pediatric Disease Priority Review Voucher it earned after the FDA approved its FAYUVI therapy. The company expects to receive $203 million in cash, which it plans to use to fund additional rare‑disease programs and to move toward profitability. The transaction is subject to standard closing conditions, including antitrust review under the Hart‑Scott‑Rodino Act. Jefferies acts as the exclusive financial advisor and Gibson Dunn & Crutcher serves as legal counsel.
Why it matters
The cash infusion provides non‑dilutive capital that can support Ultragenyx’s pipeline without issuing new shares, potentially improving its balance sheet and earnings outlook (the company said the proceeds will be used for pipeline advancement and profitability).
Key facts
- 1The voucher sale is priced at $203 million. stocktitan.net
- 2The voucher was obtained after FDA approval of FAYUVI for Sanfilippo syndrome Type A. investing.com
- 3This is Ultragenyx’s second priority‑review voucher transaction within a week. stocktitan.net
- 4Closing of the deal requires satisfaction of customary conditions, including the expiration of the Hart‑Scott‑Rodino antitrust waiting period. stocktitan.net
- 5Jefferies is the exclusive financial advisor and Gibson Dunn & Crutcher is the legal counsel for the transaction. stocktitan.net
- 6Ultragenyx shares fell 1.07% to $14.76 in early trading after the announcement. rttnews.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.